Health & Support
18 mins ago
Who Is Not A Good Candidate For Ketamine Therapy?
Nowadays, ketamine therapy has gained significant popularity for the treatment of mental health issues like…
Social illness
37 mins ago
Doctors working in paediatrics and anaesthetics at higher risk of suicidality, according to Australian survey
The recent COVID-19 pandemic exposed the stark reality of some of the challenges faced by…
Pharma News
46 mins ago
CST-2140 by CuraSen Therapeutics for Orthostatic Hypotension: Likelihood of Approval
CST-2140 is under clinical development by CuraSen Therapeutics and currently in Phase I for Orthostatic…
Pharma News
1 hour ago
Ulotaront hydrochloride by Sumitomo Pharma America for Schizophrenia: Likelihood of Approval
Ulotaront hydrochloride is under clinical development by Sumitomo Pharma America and currently in Phase III…
Pharma News
2 hours ago
Ulotaront hydrochloride by Sumitomo Pharma America for Generalized Anxiety Disorder (GAD): Likelihood of Approval
Ulotaront hydrochloride is under clinical development by Sumitomo Pharma America and currently in Phase III…
Pharma News
2 hours ago
Denosumab biosimilar by Sandoz Group for Bone Metastasis: Likelihood of Approval
Denosumab biosimilar is under clinical development by Sandoz Group and currently in Pre-Registration for Bone…
Pharma News
3 hours ago
Denosumab biosimilar by Sandoz Group for Post Menopausal Osteoporosis: Likelihood of Approval
Denosumab biosimilar is under clinical development by Sandoz Group and currently in Pre-Registration for Post…
Pharma News
3 hours ago
Denosumab biosimilar by Sandoz Group for Humoral Hypercalcemia of Malignancy: Likelihood of Approval
Denosumab biosimilar is under clinical development by Sandoz Group and currently in Pre-Registration for Humoral…
Pharma News
4 hours ago
Denosumab biosimilar by Sandoz Group for Giant Cell Tumor Of Bone: Likelihood of Approval
Denosumab biosimilar is under clinical development by Sandoz Group and currently in Pre-Registration for Giant…
Pharma News
5 hours ago
Denosumab biosimilar by Celltrion for Osteoporosis: Likelihood of Approval
Denosumab biosimilar is under clinical development by Celltrion and currently in Phase I for Osteoporosis.…